PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

BACKGROUND: Despite the utility of antiangiogenic drugs in ovarian cancer, efficacy remains limited due to resistance linked to alternate angiogenic pathways and metastasis. Therefore, we investigated PG545, an anti-angiogenic and anti-metastatic agent which is currently in Phase I clinical trials,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Winterhoff, Boris, Freyer, Luisa, Hammond, Edward, Giri, Shailendra, Mondal, Susmita, Roy, Debarshi, Teoman, Attila, Mullany, Sally A., Hoffmann, Robert, von Bismarck, Antonia, Chien, Jeremy, Block, Matthew S., Millward, Michael, Bampton, Darryn, Dredge, Keith, Shridhar, Viji
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4402130/
https://ncbi.nlm.nih.gov/pubmed/25754234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.02.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados